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Background. Plasminogen activator inhibitor-1 (PAI-1) has
been implicated in the pathogenesis of chronic kidney disease
based on its up-regulated expression and on the beneficial ef-
fects of PAI-1 inhibition or depletion in experimental models.
PAI-1 is a multifunctional protein and the mechanisms that ac-
count for its profibrotic effects have not been fully elucidated.
Methods. The present study was designed to investigate PAI-
1–dependent fibrogenic pathways by comparing the unilateral
ureteral obstruction model (UUO) (days 3, 7, and 14) in PAI-
1–overexpressing mice (PAI-1 tg) to wild-type mice, both on a
C57BL6 background.
Results. Following UUO, total kidney PAI-1 mRNA and/or
protein levels were significantly higher in the PAI-1 tg mice (N =
6 to 8/group) and fibrosis severity was significantly worse (days
3, 7, and 14), measured both as Sirius red–positive interstitial
area (e.g., 10 ± 3.2% vs. 4.5 ± 1.0%) (day 14) and total kidney
collagen (e.g., 11.1 ± 1.7 vs. 6.2 ± 1.3 lg/mg) (day 14). By day
14, the expression of two normal tubular proteins, E-cadherin
and Ksp-cadherin, were significantly lower in the PAI-1 tg mice
(3.2 ± 0.5% vs. 11.7 ± 5.9% and 2.6 ± 1.6) vs. 6.2 ± 0.8%, respec-
tively), implying more extensive tubular damage. At least four
fibrogenic pathways were differentially expressed in the PAI-1
tg mice. First, interstitial macrophage recruitment was more in-
tense (P < 0.05 days 3 and 14). Second, interstitial myofibroblast
density was greater (P < 0.05 days 3 and 7) despite similar num-
bers of proliferating tubulointerstitial cells. Third, transforming
growth factor-b1 (TGF-b1) and collagen I mRNA were signifi-
cantly higher. Finally, urokinase activity was significantly lower
(P < 0.05 days 7 and 14) despite similar mRNA levels. Gene
microarray studies documented that that the deletion of this
single profibrotic gene had far-reaching consequences on renal
cellular responses to chronic injury.
Conclusion. These data provide further evidence that PAI-1
is directly involved in interstitial fibrosis and tubular damage via
two primary overlapping mechanisms: early effects on intersti-
1See Editorial by Huang and Noble, p. 2502.
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tial cell recruitment and late effects associated with decreased
urokinase activity.
Despite many studies documenting the current world-
wide epidemic of chronic kidney disease and the rapidly
escalating costs of treating patients with end-stage kidney
disease, advances in treatment have been rather modest.
Recent investigations suggest that plasminogen activator
inhibitor-1 (PAI-1) might be an effective therapeutic tar-
get [1]. Absent in normal kidneys, the response of both
glomeruli and the tubulointerstitium to chronic injury is
characterized by local PAI-1 production [2]. Evidence for
a pathogenic role for PAI-1 in renal fibrogenesis comes
from experimental studies that report less severe renal
fibrosis and damage in PAI-1–deficient mice [3] and in
mice treated with a mutant competitive PAI-1 inhibitor
[4]. Although more controversial, humans expressing the
4G/4G polymorphic variant of the PAI-1 gene promoter
express higher plasma PAI-1 levels and these individuals
may be at increased risk for certain renal diseases such as
diabetic nephropathy [5].
The process of renal interstitial fibrogenesis can be
arbitrarily divided into four sequential and overlapping
pathogenetic mechanisms: (1) acute renal damage that
triggers a cellular phase characterized by inflammatory
cell recruitment and later the appearance of myofibrob-
lasts; (2) synthesis of profibrotic growth factors and cy-
tokines primarily by these new interstitial cells but also
by tubular cells; (3) excessive accumulation of extracel-
lular matrix proteins as productions rates increase and/or
protease-dependent degradation is inhibited; and (4) pro-
gressive nephron destruction as interstitial capillaries and
tubules are obliterated [6, 7]. Initially, the profibrotic
actions of PAI-1 seemed obvious. As a serine protease
inhibitor, PAI-1 should impair the turnover and degra-
dation of extracellular matrix proteins that accumulate
at fibrotic sites by decreasing the activity of several rel-
evant proteases: plasminogen activators, plasmin and
metalloproteases. But recently it has become less clear
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whether these proteases actually diminish fibrosis. When
the gene encoding tissue-type plasminogen activator
(tPA) was genetically deleted, matrix metalloprotease-9
(MMP-9) activity was also diminished but the tPA-null
mice developed less severe fibrosis after ureteral obstruc-
tion than wild-type mice [8]. This rather surprising out-
come was attributed to better preservation of tubular
basement membranes and fewer interstitial myofibrob-
lasts as a result of reduced epithelial-mesenchymal tran-
sition. Also of possible relevance is the ability of plasmin
to activate latent transforming growth factor-b (TGF-
b), at least in vitro. A recent experimental glomeru-
lonephritis study in PAI-1–deficient mice reported worse
glomerular damage and higher active TGF-b levels com-
pared to wild-type mice [9] although a similar study re-
ported reduced glomerular injury in PAI-1–deficient mice
[10]. In our study of the unilateral ureteral obstruction
(UUO) model, PAI-1 deficiency decreased fibrosis sever-
ity but significant differences in urokinase-type plasmino-
gen activator (uPA) and plasmin activity could not be
demonstrated [3]. A recent study by Edgtton et al [11]
found that plasminogen deficiency failed to attenuate
renal fibrosis in an obstructive uropathy model. Thus,
it remains unclear to what extent PAI-1 promotes fi-
brosis via the inhibition of protease-dependent matrix
degradation.
It is now recognized that PAI-1 exerts a powerful in-
fluence on cell migratory behavior that is dictated by the
nature of the microenvironment within which it finds it-
self and might influence the earlier cellular phase of re-
nal fibrogenesis [12–14]. Although the PAI-1 protease
inhibitory domain may be involved, the critical effect
involves interactions with vitronectin and the uPA re-
ceptor (uPAR) and at least one of several uPAR core-
ceptors [integrins, gp130, low-density lipoprotein (LDL)
receptor-associated protein/a2-macroglobulin, uPAR-
associated protein/Endo180, and mannose-6-phosphate
receptor/insulin-like growth factor type II (IGFII) recep-
tor] [15]. While many in vitro studies suggest that PAI-1
inhibits cell migration, in vivo when PAI-1 is expressed
in a more complex matrix environment, it generally pro-
motes cell migration. This latter effect has been clearly
shown in both animal models of and humans with various
adenocarcinomas [16–18]. It was therefore of interest that
the attenuation of renal fibrosis in PAI-1–deficient mice
with obstructive uropathy was associated with an impres-
sive delay in the recruitment of macrophages and my-
ofibroblasts into the interstitium, suggesting important
modulatory effects of PAI-1 on cellular behavior within
the kidney [3].
In order to gain further insights into the profibrotic
effects of PAI-1, the present study was designed to eval-
uate the consequences of PAI-1 overexpression on the
renal responses to chronic injury induced by ureteral
ligation.
METHODS
Experimental design
Studies were performed on male mice genetically en-
gineered to overexpress PAI-1 (PAI-1 tg) and wild-
type C57BL/6 mice (PAI-1 wild-type). Breeding pairs
of the PAI-1 tg mice on a C57BL/6 background
that express a murine PAI-1 minigene under the
control of a cytomegalovirus (CMV) promoter were gen-
erously provided by Dr. D. Ginsburg, Howard Hughes
Medical Institute, University of Michigan Medical Cen-
ter, Ann Arbor, Michigan [19]. The wild-type C57BL/6
mice were purchased from Harlan Laboratories (Kent,
WA, USA). The PAI-1 genotype was confirmed by North-
ern blot measurements of hepatic and kidney mRNA
levels. Both PAI-1 tg and wild-type mice were randomly
assigned into four groups: sham surgery, 3-day UUO, 7-
day UUO, and 14-day UUO. These time points were se-
lected as representative of the early phase when cellular
recruitment is just beginning (day 3), a midpoint when
growth factor–dependent matrix accumulation has begun
(day 7) and a more advanced phase when irreversible kid-
ney damage is evident (day 14). All surgeries were per-
formed under general anesthesia at the age of 16 to 20
weeks. In the UUO group, the left ureter was exposed
through a mid-abdominal incision and ligated using 4-0
silk. Sham-operated mice had their ureters exposed and
manipulated without ligaton. 5-bromo-2′-deoxyuridine
(BrdU) (Sigma Chemical Co., St. Louis, MO, USA) was
injected intraperitoneally (50 lg/g body weight) 24 hours
prior to the sacrifice to label proliferating cells. Ani-
mals were killed by exsangination under general anesthe-
sia with isoflurane; the kidneys were harvested and the
capsule removed. Livers were harvested from the 7-day
UUO groups to confirm the genotype. Each kidney was
weighed and cut into several pieces for RNA and protein
extraction and histologic studies as previously described
[20]. Frozen tissue samples were stored at −80◦C. All
procedures were performed in accordance with the guide-
lines established by National Research Council Guide for
the Care and Use of Laboratory Animals.
Histologic examination
Picrosirius red staining. To evaluate the severity of in-
terstitial fibrosis histologically, 3 lm sections of paraffin-
embedded tissue were stained with the picrosirius red.
Sections were deparaffinized by baking at 55
◦
C for 1 hour,
hydrated, and stained with picrosirius red solution (0.1%
sirius red in saturated picric acid) for 18 hours, followed
by treatment with 0.01 N HCl for 2 minutes, dehydration,
and coverslip mounting. Sections were examined by po-
larized light microscopy. The image (×400 magnification)
of five random, nonoverlapping cortical fields per each
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slide were captured using a SPOT digital camera (Diag-
nostic Instruction, Inc., Sterling Heights, MI, USA), and
the stained tubulointerstitial area was quantified using a
computer-assisted image analysis system (Image-Pro Plus
software) (Media Cybernetics, Silver Spring, MD, USA)
as previously described [21]. Results were expressed as
percentage of total tubulointerstitial area stained.
Immunostaining. Immunohistochemical staining was
performed on paraffin-embedded sections or cryosec-
tions using procedures established in our laboratory us-
ing Vectastain Elite ABC Kits (Vector Laboratories, Inc.,
Burlingame, CA, US) and AEC Substrate Chromogen
K3464 (Dako Corp., Carpinteria, CA, USA) as the per-
oxidase substrate. Horseradish peroxidase–conjugated,
F(ab′)2 goat antirat IgG (Accurate Chemical & Scientific
Corp., Westbury, NY, USA) was used to detect primary
rat monoclonal antibodies. Primary antibodies used were
reactive with mouse PAI-1 (rabbit IgG ASMPAI-GF)
(Molecular Innovations, Inc., Southfield, MI, USA), my-
ofibroblasts (peroxidase-conjugated murine antihuman
a-smooth muscle actin (a-SMA) 1A4 monoclonal anti-
body (Dako Corp.), macrophages (rat antimouse F4/80
monoclonal antibody) (Serotec, Ltd., Oxford, UK), and
proliferating cells (MAS 250 rat anti-BrdU monoclonal
antibody) (Harlan SeraLab, Ltd., Loughborough, UK),
and goat antimouse E-cadherin (R&D Systems Inc.,
Minneapolis, MN, USA). Apoptotic cell nuclei were de-
tected by terminal deoxynucleotidyl transferase(TdT)-
mediated deoxyuridine triphosphate (dUTP) nick-end
labeling (TUNEL) staining as previously described [22].
The number of positive cells was determined by manually
counting at least four randomly selected cortical fields us-
ing a 10 mm × 10 mm grid as previously described [23].
Total collagen assay
To estimate total kidney collagen content, hydroxypro-
line was measured as previously described with minor
modifications [3]. Each weighed kidney sample was hy-
drolyzed in 6 N HCl for 18 hours at 110◦C and dried by
speed vacuum centrifugation for 2 hours. Dried samples
were solublized in citric acid buffer (0.23 mol/L citric acid,
0.88 mol/L sodium acetate trihydrate, 0.85 mol/L sodium
hydroxide, and 1.2% acetic acid) and filtered through 0.45
lm centrifugal filter units (Ultrafree MC) (Millipore Co.,
Billerica, MA, USA). Samples diluted in citric acid buffer
(20 lL) were loaded into each well of a microtiter plate,
followed by 100 lL of chloramine T solution (1.4% chlo-
ramine T and 10% n-propanol in citric acid buffer). After
a 15-minute incubation at room temperature, 100 lL of
Erlich’s solution (15% p-dimethylaminobenzaldehyde,
62% n-propanol, and 18% perchloric acid) was added
and the mixture incubated for 20 minutes at 65◦C. The
optical density was read at 550 nm and the amount of
hydroxyproline was determined against a standard curve
generated using known concentrations of hydroxyproline
(Sigma Chemical Co.). Total collagen in the tissue was cal-
culated on the assumption that collagen contains 12.7%
hydroxyproline by weight. Final results were expressed
as lg collagen/mg kidney wet weight.
Renal protease activity
Plasminogen gel zymography. Pieces of frozen kid-
ney were homogenized in buffer [1% sodium dodecyl
sulfate (SDS) in 50 mmol/L Tris, pH 7.6]. The protein
concentration was determined using the BCA protein
assay (Pierce Biotechnology, Rockford, IL, USA), and
aliquots were stored at −80◦C prior to analysis. Protein
samples (10 lg) were separated by electrophoresis in
10% SDS-polyacrylamide gels containing plasminogen
(10 lg/mL) and casein (2 mg/mL). The gels were washed
with 2.5% Triton X-100 to remove SDS, and incubated
for 16 hours at 37◦C in a 0.1 mol/L glycine solution, and
stained with Coomassie brilliant blue. The gel was pho-
tographed, and the size of each lytic band was measured
using the image analysis software program. To distinguish
PAs from metalloproteinases, the samples were also run
on gel without plasminogen as previous described [3]. A
human uPA standard (Calbiochem-Novabiochem Corp.,
La Jolla, CA, USA) was loaded into the outer lane.
Northern blotting
Total kidney RNA was extracted using the Tri-
zol single-step reagent (Gibco BRL Life Technologies,
Grand Island, NY, USA). Total kidney RNA (20 lg) from
each individual animal was separated by electrophore-
sis in a 1.0% agarose formaldehyde gel, transferred to
a nylon membrane (Nytran) (Schleicher & Schuell Bio-
science, Inc., Keene, NH, USA) by capillary blotting, and
fixed by ultraviolet cross-linking. The membranes were
hybridized at 65◦C for 16 hours in a solution contain-
ing cDNA probes radiolabeled with 32P deoxycytidine
triphosphate (dCTP) (BLU-513) (Perkin Elmer Life Sci-
ences, Inc., Boston, MA, USA). Membranes were washed
twice in 2 × standard sodium citrate (SSC) with 0.1%
SDS at room temperature for 15 minutes, followed by
one wash in 0.1 × SSC with 0.1% SDS at 55◦C for 30
minutes. After washing, autoradiographs were obtained.
The results were adjusted for RNA loading inequality
based on the density of the ethidium bromide–stained
18s ribosomal bands as previously described [24]. cDNA
probes used were rat PAI-1 from Dr. T. Gelehrter (Uni-
versity of Michigan, Ann Arbor, MI, USA) [25], rat
a1(I) procollagen from Dr. S. Thorgeirsson (National
Cancer Institute, Bethesda, MD, USA) [26], rat TGF-
b1 from Dr. S. Qian (National Cancer Institute) [27], rat
uPA from Dr. J. Degen (University of Cincinnati, OH,
USA), mouse protease nexin-1 from Dr. D. Belin (Uni-
versity of Geneva, Switzerland) [28], and rat monocyte
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chemoattractant protein-1 (MCP-1) from Dr. B. Rollins,
(Dana-Farber Cancer Institute, Boston, MA, USA) [29].
Kidney gene microarray analysis
Total kidney RNA was isolated from five indi-
vidual PAI-1 wild-type mice and five PAI-1 tg mice
after 7 days of UUO using RNeasy Protect Mini kit
(Qiagen, Inc., Valencia, CA, USA) according to the
manufacturer’s instructions. RNA quantity and qual-
ity were assessed by ultraviolet spectrophotometry
(OD260/280). RNA quality was also determined using
the Agilent Bioanalyzer 2100. Five micrograms total
RNA was used for double-stranded cDNA synthesis
by Affymetrix standard procedures for Eukaryotic
target preparation. Synthesis of biotin-labeled cRNA
was carried out by in vitro transcription using the
Enzo BioArray High Yield RNA Transcript Label-
ing kit (Enzo Life Sciences, Inc., Farmingdale, NY,
USA). Each biotin-labeled target was hybridized to
Affymetrix Mouse U74Av2 arrays and processed ac-
cording to standard Affymetrix procedures (http://www.
affymetrix.com/support/technical/manuals.affx). Image
processing was performed using Affymetrix MAS-5
software. The raw data were loaded into the Rosetta
Resolver® Gene Expression Data Analysis System
(Rosetta Biosoftware, Seattle, WA, USA) using stan-
dard methods. A t test analysis was used to identify genes
differentially expressed between the two groups of five
biologic replicates for each. A P value ≤ 0.01 was consid-
ered indicative of differential expression. Gene lists were
analyzed and grouped based on Gene Ontology (GO)
description of biologic process and molecular function
as determined using the Affymetrix Gene Ontology
Mining Tool at https://www.affymetrix.com/analysis/ .
These studies were done in collaboration the Center for
Expression Arrays, University of Washington.
Western blotting
Kidney protein samples (20 lg), prepared as
described for zymography, were separated by 10%
SDS-polyacrylamide gel electrophresis (PAGE) and
transferred to nitrocellulose membranes. The pri-
mary antibodies were sheep antimouse PAI-1 IgG
(American Diagnostica Inc., Greenwich, CT, USA),
mouse anti-Ksp-cadherin (Zymed Laboratories Inc.,
South San Francisco, CA, USA), goat antimouse E-
cadherin (R&D Systems Inc.). The secondary anti-
bodies were horseradish peroxidase–conjugated rabbit
antisheep IgG (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA), horseradish peroxidase–conjugated
rabbit antimouse IgG, and horseradish peroxidase–
conjugated rat antigoat IgG (Chemicon International,
Inc., Temecula, CA, USA). Protein bands were visual-
ized using the enhanced chemiluminescence (ECL) de-
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Fig. 1. Hepatic plaminogen activator inhibitor 1 (PAI-1) mRNA lev-
els are higher in PAI-1 tg mice. The upper autoradiograph is a North-
ern blot of hepatic PAI-1 RNA isolated from mice on day 7 unilateral
ureteral obstruction (UUO). Shown below each lane is the correspond-
ing ethidium bromide–stained 18s ribosome band. The graph represents
the results of PAI-1 band density measurements expressed as mean fold
increase ± 1 SD. #P < 0.05 compared with PAI-1 wild-type (WT) group.
tection system (Pierce Biotechnology). Band intensities
were measured using the Image-Pro Plus software and
adjusted for protein loading equality as determined by
Ponceau S staining.
Statistical analysis
All data are presented as the mean ± 1 SD. Results
were analyzed by Mann-Whitney U test. A P value <0.05
was considered statistically significant.
RESULTS
PAI-1 genotyping
Hepatic PAI-1 mRNA levels at 7 days’ UUO, used as a
confirmatory measure of the genotype, were significantly
higher in PAI-1 tg mice than in wild-type mice (Fig. 1).
Renal PAI-1 expression
Renal PAI-1 mRNA was induced in response to UUO.
The mean mRNA levels were significantly higher (two- to
threefold) in PAI-1 tg mice compared to wild-type mice
at each time point (Fig. 2). Kidney PAI-1 protein levels
were higher in PAI-1 tg mice compared with wild-type
mice at each time point. By immunoblotting PAI-1 pro-
tein was detectable in PAI-1tg mice at 3 days, but it was
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Fig. 2. Kidney plasminogen activator inhibitor-1 (PAI-1) expression
levels are higher in PAI-1 tg mice after unilateral ureteral obstruction
(UUO). (A) PAI-1 mRNA. A representative PAI-1 Northern blot au-
toradiograph illustrates renal mRNA levels with 28s ribosome bands
below each lane. The graph summarizes the results of band density
measurements (N = 6/group) expressed as mean fold increase ± 1 SD.
#P < 0.05 compared with PAI-1 wild-type (WT) group at the same time
point. PAI-1 mRNA was not detectable in either sham group. (B) PAI-
1 protein. A representative Western blot illustrates the 50 kD PAI-1
protein in PAI-1 tg mice from 3 days onward, and in the wild-type mice
beginning on day 7. The graph summarizes the results of band den-
sity measurements (N = 6/group) expressed as mean fold increase ± 1
SD. #P < 0.05 compared with PAI-1 wild-type group at the same time
point. By immunostaining PAI-1 protein was strongly expressed in re-
nal tubules but also within the interstitium (day 14 shown). In general
staining intensity was greater in the PAI-1 tg mice (A) compared to
PAI-1 WT mice (B) (magnification ×400).
not identified in wild-type mice until 7 days (Fig. 2). By
immunostaining, PAI-1 protein was detected in both re-
nal tubules and the interstitium and was more intense in
the PAI-1 tg mice (Fig. 2).
Severity of renal fibrosis
The total kidney collagen content was significantly in-
creased in response to UUO in both genotypes but levels
were significantly higher in PAI-1 tg mice than in wild-
type mice at 3 days, 7 days, and 14 days (Fig. 3). By sirius
red staining, used to provide a histologic correlate to total
kidney collagen, the percentage of the tubulointerstitium
occupied by collagen was significantly greater in PAI-1 tg
mice at 7 days and 14 days (Fig. 4).
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Fig. 3. Total kidney collagen levels are significantly higher in plasmino-
gen activator inhibitor (PAI-1) tg mice. Results are expressed as mean
± 1 SD. The symbols are: () PAI-1tg mice; () PAI-1 wild-type (WT)
mice. #P < 0.05 compared to PAI-1 WT group at the same time point;
∗P < 0.05 compared to sham group of same genotype.
Profile of intrarenal PAs
By plasminogen gel zymography, urokinase (uPA) ac-
tivity was identified as a major ∼ 40 kD lytic band and a
smaller ∼ 28 kD band and represented the predominant
PA activity in kidney protein extracts. The tPA band was
barely visible at all time points. The mean kidney uPA
activity as evaluated by the size of each 40 kD band was
increased in response to UUO in both genotypes (Fig. 5).
Unlike the wild-type mice, the uPA activity was highest
in the PAI-1 tg mice at 3 days; by 14 days it was similar
to activity levels in the sham PAI-1 tg mice. The mean
uPA activity was significantly lower in PAI-1 tg mice at 7
days and 14 days than in wild-type mice. In contrast re-
nal uPA mRNA levels increased in response to UUO but
levels were similar between genotypes at all time points
(Table 1).
From our previous UUO studies we had observed that
the expression of protease nexin-1, another serine pro-
tease inhibitor that inhibits uPA, often increased in par-
allel with PAI-1 [abstract; Ikeda et al, J Am Soc Nephrol
12:722A, 2001]. In the present study it was also observed
that protease nexin-1 mRNA levels increased in response
to UUO and were significant higher in PAI-1 tg mice than
in wild-type mice at 3 days and 14 days (Table 1).
Interstitial inflammation
The renal response to UUO was characterized by
the development of an interstitial infiltrate of mono-
cytes/macrophages. The number of F4/80-positive inter-
stitial macrophages was significantly higher in PAI-1
tg mice than in wild-type mice at 3 days and 14 days
(Fig. 6). Since MCP-1 has been identified in several stud-
ies as a significantly up-regulated chemokine in UUO
[30], its expression was examined as a potential explana-
tion for the difference in macrophage numbers. As ex-
pected, renal MCP-1 mRNA levels increased in response
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Fig. 4. Interstitial fibrosis severity is worse in plasminogen activator
inhibitor (PAI-1) tg mice. (A) Graph illustrates the mean tubulointer-
stitial area occupied by collagen fibrils reactive with sirius red, expressed
as mean% area ± 1 SD. The symbols are: () PAI-1 tg mice; ) PAI-1
wild-type (WT) mice. #P < 0.05 compared with PAI-1 wild-type group
at the same time point; ∗P < 0.05 compared to sham group of same
genotype. (B) Representative sirius red photomicrographs. Panels A
to D are PAI-1 tg mice that were sham-operated, and after 3, 7, and
14 days of unilateral ureteral obstruction (UUO), respectively. Panels
E to H are PAI-1 wild-type sham, 3, 7, and 14 days UUO, respectively
(magnification 400×).
to UUO, but the mean levels were only higher in the
PAI-1 tg mice at 3 days (Table 1).
Interstitial myofibroblasts
a-SMA–positive myofibroblasts are considered the
primary source of the interstitial matrix proteins that
accumulate during fibrosis. The number of interstitial
myofibroblasts increased in response to UUO; they ap-
peared in significantly higher numbers in the PAI-1 tg
mice at 3 days and 7 days (Fig. 7). Proliferation of both
tubular and interstitial cells was activated by UUO, peak-
ing at 3 days (Table 2). However, the number of BrdU-
positive tubulointerstitial cells was similar in mice of both
genotypes, suggesting that differences in kidney cell pro-
liferation rates do not account for the early differences
in myofibroblast numbers. The number of apoptotic cells
(mainly tubular) increased progressively after UUO, but
the mean numbers were similar in the PAI-1 tg and wild-
type groups (Table 2).
Tubular epithelial cell damage
The cadherin family of proteins is a large group
of calcium-dependent, membrane-associated molecules
that are recognized as principal mediators of cell-cell ad-
hesion. Loss of E-cadherin expression has been used as
a marker of tubular epithelial-mesenchymal transition in
many studies [31]. Ksp-cadherin is a 130 kD novel cad-
herin family member that is distinct from other cadherins
in both structure and distribution as it is restricted to
the basolateral membrane of kidney tubular epithelial
cells. Loss of Ksp-cadherin expression has been used as
a composite marker of tubular cell damage and atrophy
[20]. By immunoblotting, E-cadherin protein levels after
UUO but were significantly lower in the PAI-1 tg mice
at all time points (Fig. 8). Renal Ksp-cadherin expression
decreased more rapidly in response to UUO in mice of
both genotypes; levels were significantly lower in PAI-1
tg mice than in wild-type mice at 14 days (Fig. 9).
TGF-b and procollagen genes
Given the significant early differences in interstitial cel-
lularity in PAI-1 tg, while serine protease activity was sim-
ilar until the later time points, we examined the possibility
that early differences in fibrosis severity might actually
be due to enhanced matrix production. Impressive dif-
ferences were detected, with mean renal TGF-b mRNA
levels increased in response to UUO in both genotypes
but to a significantly greater extent in the PAI-1 tg mice
at 3 days, 7 days, and 14 days (Fig. 10A). Renal procolla-
gen a1(I) mRNA levels were also significantly higher in
the PAI-1 tg mice than in wild-type mice at 7 days and 14
days (Fig. 10B).
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Fig. 5. Plasminogen gel zymogram demon-
strates delayed effects of plasminogen acti-
vator inhibitor-1 (PAI-1) expression levels on
renal urokinase-type plasmin activity (uPA).
A representative zymogram illustrates plas-
minogen lytic activity of the 40 kD uPA pro-
tein. The graph shows the mean activity ±
1 SD. Symbols are: () PAI-1 tg mice; ()
PAI-1 wild-type (WT) mice. #P < 0.05 com-
pared with PAI-1 wild-type group at same
time point; ∗P < 0.05 compared to sham group
of same genotype.
Table 1. Urokinase-type plasminogen activator (uPA), protease nexin-1, and monocyte chemoattractant protein1-1 (MCP-1) relative
mRNA levels
Sham Day 3 UUO Day 7 UUO Day 14 UUO
Gene PAI-1 tg Wild-type PAI-1 tg Wild-type PAI-1 tg Wild-type PAI-1 tg Wild-type
uPA 0.8 ± 0.4 1.0 ± 0.2 2.2 ± 0.2 2.0 ± 0.5 2.2 ± 0.3 1.8 ± 0.5 1.4 ± 0.6 1.4 ± 0.4
Nexin-1 1.0 ± 0.2 1.0 ± 0.1 11.0 ± 5.3a 4.6 ± 1.6 23.2 ± 3.4 20.0 ± 4.3 59.8 ± 5.9a 40.3 ± 1.7
MCP-1 0 0 2.0 ± 0.5 1.0 ± 0.6 2.7 ± 0.9 2.1 ± 0.8 3.9 ± 1.9 5.9 ± 1.6
Abbreviations are: UUO, unilateral ureteral obstruction; PAI-1, plasminogen activator inhibibitor-1
aP < 0.05 compared with PAI-1 wild-type group. Results are expressed as mean arbitrary densitometric units ± 1 standard deviation.
Differential gene expression profiles
Beyond regulating intrarenal serine protease activity,
the results of this study indicated that overexpression of
PAI-1 had a much broader impact on the fibrogenic re-
sponse to sustained renal injury. To gain further insight
into other pathways that might be directly or indirectly
regulated by PAI-1, differential gene expression profiles
were investigated 7 days after UUO using Affymetrix
mouse U74Av2 GeneChip with 12,488 probes; 6268 with
annotated biological function. A total of 261 genes with
annotated biologic function were significantly increased
and 203 were significantly decreased in the PAI-1 tg
mice. The differentially expressed genes and their asso-
ciated GO biologic process, molecular function, and cel-
lular component descriptions were manually scanned to
select gene families most likely to be relevant to renal
fibrosis and these are listed in Tables 3 and 4. Genes
involved in metabolic pathways, electron transport, and
transcription factors were in general not selected. Dis-
tinct genes encoding proteases/protease inhibitors, cell
adhesion molecules, proinflammatory proteins, and pro-
teins involved in cell proliferation and apoptosis were
significantly up-regulated or down-regulated in the PAI-
1 tg mice compared to the PAI-1 wild-type mice. Sev-
eral cytoskeletal genes were up-regulated in the PAI-1 tg
mice while several heat shock and defense response genes
and genes encoding transport proteins were significantly
down-regulated in the PAI-1 tg mice.
DISCUSSION
The results of this study add to the growing body of ev-
idence that PAI-1 is a key mediator of progressive kidney
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Fig. 6. Interstitial macrophage numbers are higher in plasminogen ac-
tivator inhibitor-1 (PAI-1) tg mice. (A) The graph summarizes the num-
ber of F4/80-positive interstitial macrophages per 400× field expressed
as mean number per field ± 1 SD. #P < 0.05 compared with PAI-1
wild-type (WT) group at same time point; ∗P < 0.05 compared to sham
group of same genotype. (B) Representative F4/80 immunohistochemi-
cal photomicrographs are PAI-1 tg sham, 3, 7, and 14 days UUO, panels
A to D, respectively, and PAI-1 wild-type sham, 3, 7, and 14 days UUO,
panels E to H, respectively (magnification ×400).
disease [2]. Genetically induced overexpression of PAI-1
resulted in a doubling of renal fibrosis severity compared
to wild-type animals after 14 days of ureteral obstruction.
Although measurement of renal functional differences is
not possible in the UUO model, the major structural con-
sequence of interstitial fibrosis that determines functional
decline is tubular damage and destruction [7]. Tubular
injury as evaluated by the loss of two normal tubular
epithelial cell adhesion molecules, E-cadherin and Ksp-
cadherin, was also significantly greater in PAI overex-
pressing mice after 14 days of UUO. The gene microarray
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Fig. 2. (continued)
data identified several genes encoding transport proteins
to be significantly decreased in the PAI-1 tg mice, fur-
ther evidence of more extensive tubular damage. Tubu-
lar cell death in progressive kidney disease is primarily
due to apoptosis. Several proapoptotic genes (e.g., cas-
pases 3, 4, and 7 and Bax) were significantly higher in
the gene microarray analysis of the PAI-1 tg mice and
it has been suggested that PAI-1 may be involved in the
activation of proapoptotic pathways [32]. However, just
by counting the number of TUNEL+ apoptotic cells, we
were unable to demonstrate significant PAI-1 genotype-
dependent differences, perhaps because the critical time
points were missed [33].
In addition to its well-defined role as a protease
inhibitor, PAI-1 may also modulate several cellular
functions via receptor-dependent interactions with the
urokinase receptor (uPAR) and LDL receptor-related
protein (LRP) [12–14]. The present study demonstrates
a close association between interstitial cellularity and
fibrosis severity, raising the possibility that one of the
primary profibrotic effects of PAI-1 could be to fa-
cilitate interstitial inflammatory cell and myofibroblast
recruitment. In general the intensity of interstitial inflam-
mation correlates with the severity of damage in chronic
kidney disease [34]. As a source of profibrotic growth
factors such as TGF-b , macrophages are thought to ac-
Fig. 6. (continued)
tively participate in renal fibrogenesis. In the present
study, the more aggressive fibrogenic response in the PAI-
1 tg mice was associated with worse interstitial inflam-
mation. A similar association was observed in PAI-1 tg
mice with crescentic glomerulonephritis; both glomerular
macrophage number and renal collagen content were sig-
nificantly higher in the PAI-1 overexpressing mice [10].
PAI-1 might be functioning as a macrophage chemoat-
tractant. We previously reported significantly less intersti-
tial inflammation in PAI-1–deficient mice with UUO and
proposed a potential macrophage chemotactic role for
PAI-1 based on results of an in vitro chemotaxis study [3].
Recently Degryse et al [35] have reported that PAI-1 pro-
motes smooth muscle cell chemotaxis via a pathway that
involves LRP-dependent signaling. Since LRP is ex-
pressed by renal interstitial cells in obstructive uropa-
thy [20], a similar PAI-1-LRP interaction might pro-
mote interstitial inflammation induced by chronic renal
injury.
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Fig. 7. Renal interstitial myofibroblasts ap-
pear faster in plasminogen activator inhibitor-
1 (PAI-1) tg mice. (A) The graph summa-
rizes the density of the a-smooth muscle actin
(a-SMA)–positive interstitial myofibroblasts
expressed as mean% positive area ± 1 SD.
#P < 0.05 compared with PAI-1 wild-type
(WT) group at same time point; ∗P < 0.05
compared to sham group of same geno-
type. (B) Representative a-SMA immunohis-
tochemical photomicrographs are PAI-1 tg
sham, 3, 7, and 14 days UUO, panels A to D,
respectively, and PAI-1 wild-type sham, 3, 7,
and 14 days UUO, panels E to H, respectively
(magnification ×400).
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Table 2. Proliferating and apoptotic tubulointerstitial cells
Sham Day 3 UUO Day 7 UUO Day 14 UUO
PAI-1 tg Wild-type PAI-1 tg Wild-type PAI-1 tg Wild-type PAI-1 tg Wild-type
BrdU+ 3 ± 2 5 ± 2 88 ± 13 104 ± 17 33 ± 12 52 ± 9 40 ± 11 50 ± 17
TUNEL+ 0.7 ± 0.7 1.0 ± 1.7 1.9 ± 1.1 1.4 ± 1.0 5.6 ± 2.3 6.1 ± 4.4 9.0 ± 5.6 7.7 ± 3.7
Abbreviations are: UUO, unilateral ureteral obstruction; PAI-1, plasminogen activator protein-1; BrdU, 5-bromo-2′-deoxyuridine; TUNEL, terminal deoxynucleotidyl
transferase(TdT)-mediated deoxyuridine triphosphate (dUTP) nick-end labeling. Results are expressed as mean number of positive tubulointerstitial cells per 400×
field ± 1 standard deviation.
Although plausible, it seems less likely that PAI-1 pro-
motes monocyte migration indirectly via a coordinated
up-regulation of chemokines or adhesion molecules.
MCP mRNA levels were only significantly higher in
the PAI-1 tg mice 3 days after UUO. Gene microar-
ray data on day 7 failed to identify other chemokines
or leukocyte adhesion molecules as significantly up-
regulated in PAI-1 tg mice.
PAI-1 may also modulate cellular adhesion and mi-
gration via interactions between vitronectin, integrins,
uPAR, and uPA [12–14]. This interplay is complex and
highly dependent on the composition of the local en-
vironment but in general the high affinity of PAI-1 for
vitronectin facilitates integrin-dependent (avb 3 in par-
ticular) cell migration whenever the extracellular en-
vironment contains alternative integrin ligands such as
fibronectin. PAI-1 interacting with uPA-uPAR and av in-
tegrins may also detach cells adherent to extracellular
matrices and promote integrin-dependent clearance by
endocytosis [36]. While the functional consequences of
monocyte “detachment” within the kidney are open to
speculation, it is tempting to suggest that directed migra-
tion to chemokines might be facilitated.
The extent to which the protease inhibitory actions of
PAI-1 regulate the migration of inflammatory cells into
the renal interstitium is currently unclear. Urokinase is
the predominant serine protease in the renal tubuloint-
erstitial compartment and the present as well as earlier
studies have reported increased uPA mRNA expression
and activity levels in the UUO model [3]. By cleaving
its receptor to release soluble uPAR, urokinase may pro-
mote monocyte recruitment, as soluble uPAR interacts
with the chemoattraction receptor FPRL1/LXA4 [37].
In vivo, mice lacking uPAR have significantly lower re-
nal uPA activity and fewer interstitial macrophages than
wild-type mice after ureteral obstruction [22]. Despite
similar uPA mRNA levels in the PAI-1 tg and wild-
type mice, renal uPA activity was significantly lower
in the PAI-1–overexpressing mice but not until day
7. Therefore, uPA-dependent chemotaxis does not ex-
plain the early differences in interstitial macrophage
numbers.
Interstitial macrophages may contribute directly to
progressive kidney disease via several mechanisms, the
most important possibly being the synthesis of fibrogenic
growth factors [34]. In support of this paradigm, the PAI-
1 tg mice with worse tubulointerstitial disease had sig-
nificantly higher renal TGF-b mRNA levels on days 3
and 14 after UUO, paralleling the significant differences
in interstitial macrophage numbers. Data derived from
microarray analysis of differential gene expression iden-
tified several other cytokines and growth factor receptors
that were significantly increased in the PAI- 1-tg mice [in-
cluding receptors for interleukin-4 (IL-4), tumor necro-
sis factor (TNF), fibroblast growth factor (FGF), activin,
leukemia inhibitory factor, and retinoic acid]. The en-
hanced expression of these receptors might simply be at-
tributed to the greater number of macrophages in the
PAI-1 tg mice or alternatively it may be these intrarenal
macrophages are phenotypically and functionally distinct
from macrophages in the kidneys of the wild-type mice—
differences that might further contribute to accelerated
fibrosis in the PAI-1-tg mice.
The second interstitial cell that is a critical mediator
of progressive kidney disease is the myofibroblast. As
in our previous study in PAI-1–deficient mice, PAI-1 ex-
pression levels had a significant impact on the rate of
recruitment of interstitial myofibroblasts. Both 3 and 7
days after UUO, there were twice as many interstitial
myofibroblasts in PAI-1-tg mice. After this early phase
of injury, the number of interstitial myofibroblasts in the
wild-type mice caught up to the PAI-1 tg mice. Although
the origin of renal interstitial myofibroblasts is still un-
clear, current evidence supports four distinct possibili-
ties and the findings in this study suggest that PAI-1 may
be directly involved in one or more of them. First, my-
ofibroblasts may be recruited from circulating precursor
cells although the contribution of this pathway appears
to be modest [38–40]. Second, normal a-SMA–expressing
perivascular cells might migrate into the interstitium un-
der the influence of appropriate signals [41]. It is possible
that like its effects on monocytes, PAI-1 facilitates the
recruitment of interstitial myofibroblast precursor cells
from the circulation or perivascular locations.
Third, resident interstitial fibroblasts may transform
into myofibroblasts upon activation. Even though the
proliferative rate of resident interstitial fibroblasts may
be relatively low in response to damage, this pathway
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Fig. 8. Renal loss of E-cadherin occurs more
rapidly in plasminogen activator inhibitor-1
(PAI-1) tg mice. The upper Western blot illus-
trates the changes in E-cadherin protein levels
(126 kD) on 14 days’ unilateral ureteral ob-
struction (UUO). Ponceau S staining shown
below demonstrates the equivalency of pro-
tein loading and transfer. The graph sum-
marizes the results of single band density
measurements (N = 6/group/time point) ex-
pressed as mean fold increase±1 SD. Symbols
are: () PAI-1 tg mice; () PAI-1 wild-type
(WT) mice. #P < 0.05 compared with PAI-1
wild-type group at same time point; ∗P < 0.05
compared with sham group of same genotype.
Below, light photomicrographs of E-cadherin
immunostaining are PAI-1 tg mice (A) and
PAI-1 wild-type mice (C) in sham-operated
group and PAI-1 tg mice (B) and PAI-1 wild-
type mice (D) from the 14 days’ UUO group
(magnification ×400).
may contribute substantially to the myofibroblast popu-
lation given their long half-life [24, 42, 43]. In the present
study, most of the cells that proliferated after UUO
were tubular cells. The numbers of BrdU-positive tubu-
lointerstitial cells were similar in both genotypes sug-
gesting that PAI-1 alone does not modulate fibroblast
proliferative rates, even though several genes involved in
proliferation were differentially expressed between the
PAI-1 tg and the PAI-1 wild-type mice.
The final pathway of myofibroblast recruitment is
epithelial-mesenchymal transition (EMT). At least three
key events are involved in the EMT process that leads
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Fig. 9. Renal loss of Ksp-cadherin occurs more rapidly in plasminogen
activator inhibitor (PAI-1) tg mice. The upper Western blots demon-
strate a time-dependent alteration in Ksp-cadherin (130 kD) expression.
Ponceau S staining shown in the lower portion illustrates the equiva-
lency of protein loading and transfer. The graph summarizes the results
of single band density measurements expressed as mean fold increase
± 1 SD. Symbols are: () PAI-1 tg mice; ) PAI-1 wild-type (WT) mice.
#P < 0.05 compared with PAI-1 wild-type group at same time point; ∗P
< 0.05 compared with sham group of same genotype.
to the appearance of these cells in the interstitium [31].
First, tubular epithelial cells must undergo phenotypic
transformation, an event that is often identified experi-
mentally by the loss of tubular cell adhesion molecules
such as E-cadherin and the de novo expression of fibrob-
last proteins such as FSP-1 and a-SMA. In response to
UUO, tubular cells produce PAI-1 and the rate of E-
cadherin loss was significantly greater in the PAI-1 tg
mice. Whether PAI-1 plays a direct role in the phenotypic
transformation of tubular epithelial cells or whether the
acceleration of this change in the PAI-1 tg mice is a con-
sequence of the more aggressive inflammatory and fibro-
genic responses cannot be determined by the present
study. A direct tubular effect of PAI-1 would require
the existence of a currently unknown PAI-1 receptor.
Whether interactions with uPAR/uPA and basolateral
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Fig. 10. Renal transforming growth factor-b (TGF-b) and a1(I) pro-
collagen mRNA levels are higher in plasminogen activator inhibitor
(PAI-1) tg mice. The autoradiographs of TGF-b (A) and a1(I) procol-
lagen (B) are the Northern blots with 18s ribosome bands shows below
each lane. The graphs summarize the results of each band density mea-
surements (N = 6) expressed as mean fold increase ± 1 SD. #P < 0.05
compared with PAI-1 wild-type (WT) group at same time point; ∗P <
0.05 compared with sham group of same genotype.
LRP-1 or apical LRP-2 (megalin) could serve such a role
deserves further consideration [44].
The second step requires disruption of the barrier be-
tween tubular cells and the interstitium that is imposed
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Table 3. Genes significantly increased in plasminogen activator inhibitor-1 (PAI-1) tg mice
Proteases/inhibitors
Serine (or cysteine) proteinase inhibitor, clade A, member 1b Serpina1b
Serine (or cysteine) proteinase inhibitor, clade A, member 1a Serpina1a
Alanyl (membrane) aminopeptidase Anpep
Calpain 1 Capn1
Calpain 5 Capn5
Cathepsin F Ctsf
Procollagen C-proteinase enhancer protein Pcolce
Prolyl endopeptidase Prep
Cathepsin B Ctsb
Cytokines/growth factors
Insulin-like growth factor binding protein, acid labile subunit Igfals
Interleukin-4 receptor, alpha Il4ra
Tumor necrosis factor receptor superfamily, member 1b Tnfrsf1b
Milk fat globule-epidermal growth factor 8 protein Mfge8
Fibroblast growth factor receptor 1 Fgfr1
Activin A receptor, type II-like 1 Acvrl1
Activin receptor IIB Acvr2b
Insulin-like growth factor binding protein 1 Igfbp1
Leukemia inhibitory factor receptor Lifr
Cell adhesion/communication
Ninjurin 1 Ninj1
Flotillin 2 Flot2
SH3 domain protein 4 Sh3d4
Junction plakoglobin Jup
Integrin beta5 Itgb5
Gap junction membrane channel protein beta 2 Gjb2
Ras homolog gene family, member A Arha
Carboxypeptidase × 2 (M14 family) Cpxm2
Inflammation/immune response
Scavenger receptor class B, member 1 Scarb1
Lymphocyte antigen 6 complex, locus E Ly6e
TAP binding protein Tapbp
Ia-associated invariant chain Ii
Histocompatibility 2, class II, locus Mb1 H2-DMb1
Histocompatibility 2, class II antigen E beta H2-Eb1
Histocompatibility 2, class II, locus DMa H2-DMa
Proteasome (prosome, macropain) 28 subunit, alpha Psme1
Lymphotoxin B Ltb
Protein tyrosine phosphatase, nonreceptor type substrate 1 Ptpns1
Proliferation
Par-6 (partitioning defective 6,) homolog alpha (C. elegans) Pard6a
Bridging integrator 1 Bin1
Nuclear factor of activated T cells, cytoplasmic 1 Nfatc1
Neuroblastoma, suppression of tumorigenicity 1 Nbl1
Schlafen 2 Slfn2
Cell division cycle 37 homolog (S. cerevisiae) Cdc37
Growth arrest and DNA-damage-inducible 45 beta Gadd45b
Mitogen activated protein kinase kinase 7 Map2k7
Midkine Mdk
v-crk sarcoma virus CT10 oncogene homolog (avian)-like Crkl
Thymoma viral proto-oncogene 2 Akt2
v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) Erbb3
Stratifin Sfn
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian) Maff
Jun-B oncogene Junb
Block of proliferation 1 Bop1
Apoptosis
Bcl2-associated X protein (BAX) Bax
Lymphocyte-specific 1 Lsp1
Caspase 3, apoptosis-related cysteine protease Casp3
Defender against cell death 1 Dad1
Caspase 4, apoptosis-related cysteine protease Casp4
Caspase 7 Casp7
Cytoskeleton
Actin-related protein 2/3 complex, subunit 1A Arpc1a
Paralemmin Palm
Par-6 (partitioning defective 6) homolog alpha (C. elegans) Pard6a
Microtubule-associated protein tau Mapt
Tubulin, alpha 6 Tuba6
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Table 3. Continued.
Tubulin, alpha 1 Tuba1
Erythrocyte protein band 4.1 Epb4.1
Synaptogyrin 1 Synaptogyrin 1
Cofilin 1, nonmuscle Cﬂ1
Development
LIM domain binding 1 Ldb1
Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B Sema3b
Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4A Sema4a
Ephrin B1 Efnb1
Male-enhanced antigen 1 Mea1
Dickkopf homolog 3 (Xenopus laevis) Dkk3
Frizzled homolog 1 (Drosophila) Fzd1
COP9 (constitutive photomorphogenic) homolog, subunit 3 (Arabidopsis thaliana) Cops3
Homeo box D10 Hoxd10
Homeo box A11 Hoxa11
Retinoic acid receptor, alpha Rara
Stimulated by retinoic acid gene 6 Stra6
Miscellaneous
Peroxisome proliferators-activated receptor alpha Ppara
Amyloid beta (A4) precursor protein-binding, family A, member 3 Apba3
Leukotriene C4 synthase Ltc4s
Peroxiredoxin 2 Prdx2
Angiotensinogen Agt
Retinoic acid receptor, gamma Rarg
Growth arrest specific 6 Gas6
by the tubular basement membrane. Mediated by matrix-
degrading proteases, it is easy to envisage how PAI-1
might block rather than promote tubular basement mem-
brane damage since the activity of PAs, plasmin and
plasmin-activated metalloproteinases should, if anything,
be decreased in the presence of excessive PAI-1. During
the third step, transdifferentiated tubular cells migrate
into the interstitium. Little is currently known about the
signals that control this migration but PAI-1 could poten-
tially have a modulatory role.
One of the more surprising findings in the present and
other recent studies is the lack of compelling in vivo ev-
idence that the profibrotic effects of PAI-1 are tightly
associated with its inhibitory effects on proteases. Renal
urokinase activity was significantly lower in the PAI-1 tg
mice on days 7 and 14 while the differences in inflamma-
tion and fibrosis began much earlier, on day 3. It is possi-
ble that the assays were not sufficiently sensitive to detect
early differences, but it is also plausible that the protease-
dependent effects of PAI-1 are less prominent, especially
during the initial phase of chronic injury. PAs are thought
to be particularly important in fibrotic responses that are
associated with fibrin provisional matrices such as oc-
curs in the lung, although surprisingly, genetic fibrino-
gen deficiency does not alter the severity of pulmonary
fibrosis in mice treated with bleomycin [45, 46]. In the
kidney tPA but not uPA deficiency exacerbates the sever-
ity of crescentic glomerulonephritis associated with fib-
rin deposition [47]. In contrast, tPA deficiency actually
attenuates the severity of renal fibrosis induced by UUO
possibly due to reduced MMP-9 activity, better preser-
vation of tubular basement membranes and as a con-
sequence, a reduction in the size of the interstitial my-
ofibroblast population [8]. Direct antifibrotic actions for
uPA appear more compelling based on experiments us-
ing urokinase therapy in models of pulmonary and hep-
atic fibrosis although data from renal models of pro-
gressive tubulointerstitial disease are not yet available
[48–50]. The role of plasmin in fibrosis is complicated by
the fact that it may either promote fibrosis by activating
latent TGF-b or it may counteract fibrosis by activating
latent metalloproteinases. Recent work based on stud-
ies of obstructive uropathy in plasminogen-deficient mice
from our own and another laboratory suggest that the
net in vivo effect of plasmin in the kidney is the enhance-
ment of fibrosis (Zhang et al, manuscript in preparation)
[11].
Does PAI-1 promote renal fibrosis by inhibiting matrix
turnover? The present study cannot answer this question.
The accelerated inflammation and myofibroblast recruit-
ment associated with higher TGF-b and procollagen I
mRNA levels indicate that matrix production rates were
likely higher in PAI-1 tg mice but delayed degradation
due to lower uPA activity remains plausible. Another
genotype-dependent difference was identified that could
contribute to impaired matrix turnover in PAI-1 tg mice.
Given our earlier observation that the serine protease in-
hibitor protease nexin-1 and PAI-1 might be coregulated
[abstract; Ikeda et al, J Am Soc Nephrol 12:722A, 2001],
its expression was examined in the present study and
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Table 4. Genes significantly decreased in plasminogen activator inhibitor-1 (PAI-1) tg mice
Proteases/inhibitors
Tissue inhibitor of metalloproteinase 3 Timp3
Annexin A3 Anxa3
Serine (or cysteine) proteinase inhibitor, clade I, member 1 Serpini1
Serine protease inhibitor, Kazal type 3 Spink3
Phosphate-regulating gene with homologies to endopeptidases on the X chromosome Phex
Cytokines
Interferon-related developmental regulator 1 Ifrd1
S100 calcium binding protein A11 (calizzarin) S100a11
Serine/threonine kinase receptor associated protein Strap
Insulin-like growth factor 1 Igf1
Platelet derived growth factor, alpha Pdgfa
Insulin-like growth factor binding protein 5 Igfbp5
Suppressor of cytokine signaling 2 Socs2
Cell adhesion
Laminin B1 subunit 1 Lamb1-1
Vascular cell adhesion molecule 1 Vcam1
Nidogen 1 Nid1
Cadherin 11 Cdh11
Thrombospondin 1 Thbs1
Calcium and integrin binding 1 (calmyrin) Cib1
Secreted phosphoprotein 1 Spp1
Tight junction protein 1 Tjp1
CEA-related cell adhesion molecule 9 Ceacam9
Integrin beta 1 (fibronectin receptor beta) Itgb1
Proliferation
Septin 2 2-Sep
Centrin 3 Cetn3
Checkpoint kinase 1 homolog (S. pombe) Chek1
Topoisomerase (DNA) II beta Top2b
RAD21 homolog (S. pombe) Rad21
Origin recognition complex, subunit 4-like (S. cerevisiae) Orc4l
Nuclear factor I/B Nﬁb
Thioredoxin-like Txnl
Protein phosphatase 3, catalytic subunit, alpha isoform Ppp3ca
Cyclin G1 Ccng1
Phospholipase C, beta 1 Plcb1
Ribosomal protein S4, X-linked Rps4x
Myelocytomatosis oncogene Myc
Apoptosis
Programmed cell death 6 Pdcd6
Tial1 cytotoxic granule-associated RNA binding protein-like 1 Tial1
Cytotoxic granule-associated RNA binding protein 1 Tia1
Growth arrest specific 2 Gas2
Carboxypeptidase E Cpe
A disintegrin and metalloproteinase domain 9 (meltrin gamma) Adam9
A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 1 Adamts1
Proliferation-associated 2G4 Pa2g4
Proprotein convertase subtilisin/kexin type 5 Pcsk5
Glutamyl aminopeptidase Enpep
Heat response
Heat-responsive protein 12 Hrsp12
Heat shock protein 1 (chaperonin 10) Hspe1
Heat shock protein 8 Hspa8
Heat shock 70 kD protein 5 (glucose-regulated protein) Hspa5
Heat shock protein 1A Hspa1a
Heat shock protein 105 Hsp105
Defense responses
CD24a antigen Cd24a
Periplakin Ppl
Beta-2 microglobulin B2m
Histocompatibility 2, D region locus 1 H2-D1
Catalase Cat
Immunoglobulin kappa chain variable 1 (V1) Igk-V1
Immunoglobulin heavy chain (J558 family) Igh-VJ558
Immunoglobulin heavy chain (V7183 family) Igh-V7183
Immunoglobulin joining chain Igj
T-cell cytokine receptor Tccr
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Table 4. Continued.
Complement
Complement component factor h-like 1 Cfhl1
Complement component factor h Cfh
Adipocyte complement-related protein Acrp30
Transport
ATPase, H+ transporting, V1 subunit B, isoform 2 Atp6v1b2
ATPase, H+ transporting, V1 subunit C, isoform 1 Atp6v1c1
Voltage-dependent anion channel 3 Vdac3
Chloride channel calcium activated 1 Clca1
Chloride channel 4 - 2 Clcn4 - 2
Folate receptor 2 (fetal) Folr2
Albumin 1 Alb1
Hippocampus abundant gene transcript 1 Hiat1
Fatty acid binding protein 4, adipocyte Fabp4
Solute carrier family 7 (cationic amino acid transporter, y+ system), member 10 Slc7a10
SMC2 structural maintenance of chromosomes 2-like 1 (yeast) Smc2l1
Adaptor-related protein complex 3, sigma 1 subunit Ap3s1
Cystic fibrosis transmembrane conductance regulator homologue Cftr
Purinergic receptor P2X, ligand-gated ion channel, 1 P2rx1
Potassium voltage-gated channel, shaker-related subfamily, member 1 Kcna1
Solute carrier family 12, member 2 Slc12a2
Solute carrier family 35 (CMP-sialic acid transporter), member 1 Slc35a1
Miscellaneous
Immediate early response 5 Ier5
Kidney androgen regulated protein Kap
Cd63 antigen Cd63
Neuroepithelial cell transforming gene 1 Net1
Growth hormone Gh
Progesterone receptor membrane component 1 Pgrmc1
Mannose receptor, C type 1 Mrc1
Intelectin Itln
Disabled homologue 1 (Drosophila) Dab1
Ephrin B3 Efnb3
Dishevelled, dsh homologue 1 (Drosophila) Dvl1
Tuftelin 1 Tuft1
von Hippel-Lindau binding protein 1 Vbp1
Endothelin 1 Edn1
ras homolog gene family, member B Arhb
found to be significantly higher at 3 and 14 days. Protease
nexin-1 inhibits uPA, plasmin, and thrombin, and it has
been implicated in dysregulated matrix turnover associ-
ated with such disease processes as malignancy, glomeru-
lonephritis and scleroderma [51–53]. The gene microar-
ray data identified additional proteases and protease
inhibitors that were differentially expressed between the
genotypes that could potentially impact matrix remodel-
ing and degradation.
CONCLUSION
The present study in PAI-1–overexpressing mice adds
to the growing body of evidence that it has a very im-
pressive fibrosis-promoting role. First recognized as a
protease inhibitor, it is becoming increasingly clear that
PAI-1 also plays an important role in the interstitial
recruitment of inflammatory macrophages and myofi-
broblasts, especially during the early response to chronic
injury. Our data suggest that these cellular effects are fun-
damental to the role of PAI-1 as a fibrogenic molecule.
As the fibrogenic response progresses, modulatory ef-
fects on uPA activity are present that may further en-
hance matrix accumulation by impairing its turnover.
Data from gene microarray studies demonstrate how the
overexpression of this single profibrotic molecule has
far-reaching effects on the renal molecular response to
chronic damage. These data suggest that PAI-1 should be
an excellent therapeutic target for chronic kidney disease
prevention.
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